BMS-193884 and BMS-207940 Bristol-Myers Squibb.
Bristol-Myers Squibb is developing BMS-193884, an oral endothelin antagonist, for the potential treatment of congestive heart failure (CHF) and pulmonary hypertension [206604]. The compound entered phase I trials in November 1996 [242721] and had progressed to phase II trials [399460], [441398]. Structural modifications led to the development of a second-generation analog, BMS-207940, a biphenylsulfonamide endothelin A receptor-selective antagonist, and the probable discontinuation of the first clinical candidate, BMS-193884 [446511]. By April 2002, BMS-207940 was in phase I trials [446511]. By March 2002, filing for NDA was expected to take place in 2004 at the earliest [452734].
Department of Pediatric Cardiology, Georg-August-University, Göttingen, Germany.
Martin
M
Hulpke-Wette
Reiner
R
Buchhorn
D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004345:Drug Industry / Q000379:methods*; D065128:Endothelin Receptor Antagonists; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D010080:Oxazoles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D013449:Sulfonamides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
C412823:BMS 193884; D065128:Endothelin Receptor Antagonists; C470655:N-((2'-(((4,5-dimethyl-3-isoxazolyl)amino)sulfonyl)-4-(2-oxazolyl)(1,1'-biphenyl)-2-yl)methyl)-N,3,3-trimethylbutanamide; D010080:Oxazoles; D013449:Sulfonamides